Table 2.

First line palliative treatment of advanced SCCHN

	Responders	Non responders	NE	PFS	OS
Cetuximaba	16.5%	82.5%	1%	2.8 m	5.8 m
Cisplatin and Placebob	10%	90%		2.7 m	7.9 m
Cisplatin and Fluorouracil c	29.8%	59.6%	10.6	NS	8.7 m
Cisplatin and Paclitaxelc	26%	60%	14	NS	8.1 m
Ciplatin and Cetuximabb	26%	74%		4.2 m	9.2 m

NE, not evaluable; PFS, progression free: survival; OS, overall survival; m, months; NS, not stated.

^a Trigo et al (2004).

^b Burtness et al (2005).

^cGibson et al (2005).